APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View™ Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex™ arrays from Protein Biotechnologies.

“We are excited about how Gentel's easy-to-use kits and affordable system can help make arrays accessible to whole a new group of users.”

Alex Vodenlich, Gentel's President and CEO, said of the product, "This launch expands the applications of APiX technology to include not only antibody and protein arrays on clear glass slides, but also tumor lysate arrays on porous nitrocellulose surfaces. Now virtually any commercial protein microarray can take advantage of Gentel's chromogenic detection."

APiX chromogenic technology allows for the detection of any biotinylated molecule, generating light grey-to-black spots that are visible to the naked eye and can be scanned with the Gentel Proteomics Multi-System. APiX is also compatible with a variety of secondary antibodies such as anti-mouse and anti-rabbit. APiX uses a proprietary gold-catalyzed silver deposition and typically achieves measurably improved sensitivity compared to fluorescence detection.

Phillip Schwartz, President and CEO of Protein Biotechnologies recognized the potential of the Gentel reagents and system for use with Protein Biotechnologies' SomaPlex™ tumor lysate arrays. "Our customers are looking for a simple, sensitive, and affordable detection method for use with SomaPlex™ arrays. The Gentel Proteomics Multi-System meets this need," stated Schwartz. "We are excited about how Gentel's easy-to-use kits and affordable system can help make arrays accessible to whole a new group of users."

Tumor lysates arrays are a type of reverse phase protein microarray that contains a collection of up to several hundred tumor samples on slide. Antibodies or other probes are applied to the array to detect the abundance of specific protein biomarkers and rapidly measure expression across a large population of tumor samples. Array results are then compared to demographic and relevant clinical disease-specific data on the tumor collection to draw a conclusion.

APiX View detection reagents are compatible with the Gentel Proteomics Multi-System, which provides "scan-to-analysis" functionality for multiplex immunoassays, tumor lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blocking CDK7 protein could prevent heart damage associated with cancer treatment